The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...
Traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy for patients with BRAF-mutated ...
Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate ...
SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--February 24, 2026-- ...
Colorectal liver metastases (CRLM), cancer that has spread from the colon or rectum to the liver, have a deadly reputation. Due to its pervasive spread, typical cancer treatments like chemotherapy and ...
Earlier in February 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, ...
Oncolytics Biotech said it will now focus on registrational and registration-enabling studies in squamous cell anal cancer and metastatic colorectal cancer after concluding enrollment in its Goblet ...
The FDA has granted full approval to Pfizer Inc.’s Braftovi when used with Eli Lilly’s Erbitux (cetuximab) and fluorouracil‑based chemotherapy for adults with metastatic colorectal cancer carrying a ...
Colon cancer diagnosis involves colonoscopy, imaging, and blood tests, with staging guiding treatment decisions. Stage 1 treatment typically involves surgery, while stage 2 may include chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results